Hồ sơ nguồn sơ cấp
Lakewood-Amedex announced positive preclinical results showing intravesical Bisphosphocin Nu-8 achieved up to 97% inhibition of E. coli growth in a rodent UTI model versus no effect in vehicle control. This is the first reported efficacy data for the compound in urinary tract and pulmonary infection indications.
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group. SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT,...